Amneal (AMRX) Co-CEO gains shares via RSU and performance awards

Rhea-AI Filing Summary

Amneal Pharmaceuticals, Inc. President & Co-CEO Chirag K. Patel reported multiple equity award vestings and related share movements. On March 3, 2026, performance-based restricted stock units covering 733,944 units vested after achieving a performance threshold that resulted in vesting of 200% of the targeted number, and were settled into the same number of Class A Common shares on a one-for-one basis. Additional restricted stock units covering 59,931 units also converted into Class A Common Stock.

To cover tax withholding obligations from these vestings, the reporting person disposed of 297,537 and 15,616 Class A shares at per-share prices of $13.31, and on March 4, 2026 disposed of a further 37,825 Class A shares at $13.30, all characterized as share withholding rather than open-market sales. After these transactions, direct holdings reported include 1,393,470 shares of Class A Common Stock and 185,185 restricted stock units, with an additional 21,269,420 Class A shares held indirectly through family trusts.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Patel Chirag K.

(Last) (First) (Middle)

C/O AMNEAL PHARMACEUTICALS, INC.

400 CROSSING BOULEVARD

(Street)

BRIDGEWATER NJ 08807

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Amneal Pharmaceuticals, Inc. [ AMRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & Co-CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	03/03/2026		M		59,931(1)	A	(2)	917,911	D
Class A Common Stock	03/03/2026		F		15,616(3)	D	$13.31	902,295	D
Class A Common Stock	03/03/2026		M		733,944	A	(4)	1,636,239	D
Class A Common Stock	03/03/2026		F		297,537(5)	D	$13.31	1,338,702	D
Class A Common Stock	03/04/2026		M		92,593(1)	A	(2)	1,431,295	D
Class A Common Stock	03/04/2026		F		37,825(3)	D	$13.3	1,393,470	D
Class A Common Stock								21,269,420	I	By Family Trusts

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	03/03/2026		M			59,931	(6)	(6)	Class A Common Stock	59,931	$0	179,795	D
Performance-Based Restricted Stock Units	(4)	03/03/2026		M			733,944	(4)	(4)	Class A Common Stock	733,944	$0	0	D
Restricted Stock Units	(2)	03/04/2026		M			92,593	(7)	(7)	Class A Common Stock	92,593	$0	185,185	D

Explanation of Responses:

1. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.

2. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.

3. Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.

4. Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5.

5. Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units.

6. On March 3, 2025, the Reporting Person was granted 239,726 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

7. On March 4, 2024, the reporting person was granted 370,370 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

Remarks:

	/s/ Denis Butkovic, Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did AMRX President & Co-CEO Chirag Patel report?

Chirag K. Patel reported RSU and performance-based RSU vestings converting into Class A Common Stock, plus related share withholding to cover taxes. These movements changed his reported direct and indirect ownership positions in Amneal’s Class A shares and restricted stock units.

How many performance-based RSUs vested for AMRX’s Co-CEO in March 2026?

Performance-based restricted stock units covering 733,944 units were certified as meeting the performance threshold and vested on March 3, 2026. They reflected 200% of the targeted number and were settled into an equal number of Amneal Class A Common shares on a one-for-one basis.

Were the AMRX insider share disposals open-market sales or tax withholding?

The reported disposals were characterized as shares withheld to satisfy tax withholding obligations from RSU and performance-based RSU vesting. Transactions coded “F” at prices around $13.30 per share reflect tax-withholding disposition, not discretionary open-market sales by the insider.

What are Chirag Patel’s reported direct holdings of AMRX Class A stock after these transactions?

Following the March 3–4, 2026 transactions, Chirag K. Patel reported direct ownership of 1,393,470 shares of Amneal Class A Common Stock. He also reported 185,185 restricted stock units as directly held awards that represent contingent rights to receive additional Class A shares.

How many AMRX shares are reported as indirectly owned through family trusts?

The filing reports 21,269,420 shares of Amneal Class A Common Stock held indirectly by family trusts. These indirect holdings are separate from Chirag K. Patel’s directly owned shares and restricted stock units and are identified with an indirect ownership code tied to family trusts.

What new RSU grants to AMRX’s Co-CEO are disclosed in the footnotes?

Footnotes state that on March 3, 2025, Chirag K. Patel was granted 239,726 restricted stock units, vesting in four equal installments from the first anniversary. On March 4, 2024, he was granted 370,370 restricted stock units with the same four-installment vesting structure.